HealthQuill
Eli Lilly’s Alzheimer’s experimental drug, donanedab, slowed down cognitive and functional decline in people with early symptoms of the disease, according to a company statement.
Health Research

Key protein ArfGAP2 identified as driver of autoimmune diseases

HQ Team March 20, 2025: Researchers have identified a protein, ArfGAP2, that triggers harmful immune responses in autoimmune diseases, offering a novel target.

Read More
Eight people have died in Rwanda due to Marburg virus disease and 26 others were confirmed to be infected by the illness — the first such in the eastern-central African nation.
Drugs Research

Study uncovers protein’s dual role in sepsis, offering new treatment hope

HQ Team March 18, 2025: Sepsis, a life-threatening response to infection that triggers organ failure, claims over 11 million lives worldwide annually, according.

Read More
The UNICEF and the private-public partnership Gavi Vaccine Alliance will roll out its malaria vaccine for the first time in nine African countries to fight one of the deadliest diseases in the continent, according to the WHO.
Drugs Health

Abrupt cessation of US funds could lead to 3 million HIV-related deaths: WHO

HQ Times March 18, 2025: The strides made in disease containment and eradication such as malaria, HIV, and tuberculosis in the last 20.

Read More
Drugs Research

Celon Pharma’s pill shows promise in reducing dyskinesia in Parkinson’s trial

HQ Team March 17, 2025: Celon Pharma’s human trial with PDE10A inhibitor, CPL’36, has achieved statistically significant reductions in involuntary movements caused by.

Read More
British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an end-stage trial, according to a joint statement.
Pharma

AstraZeneca acquires EsoBiotec for $1billion in a bid to push its cell therapy agenda

HQ Team March 17, 2025: AstraZeneca has announced plans to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies, for up to.

Read More
Eneboparatide (AZP-3601) meets its primary goal in the CALYPSO Phase III trial, offering hope for chronic hypoparathyroidism patients.
Drugs

Eneboparatide succeeds in Phase III trial for chronic hypoparathyroidism

HQ Team March 17, 2025: The Phase III CALYPSO trial, led by Alexion, AstraZeneca Rare Disease, has shown promising results for eneboparatide (AZP-3601),.

Read More
Grey matter in the human brain may be linked to the start of adolescent smoking and nicotine addiction — a study that may have implications for prevention and treatment.
Health Research

MIT’s 40Hz gamma stimulation shows promise in slowing Alzheimer’s progression

HQ Team March 15, 2025: A decade of research at MIT’s Picower Institute for Learning and Memory has brought hope to millions battling.

Read More
Australian team performs titanium heart transplant on a man who survives outside hospital setting awaiting heart translant
Health

Australian man becomes world’s first to leave hospital with titanium heart

HQ Team March 15, 2025: An Australian man in his forties has become the first person in the world to be discharged from.

Read More
ADHD medicine
Drugs

UN narcotics agency places 6 new substances under international control

March 14, 2025 –The United Nations Commission on Narcotic Drugs (CND) has decided to place five new psychoactive substances and one medicine under.

Read More
The first dosing in a late-stage trial to evaluate an investigational drug for tuberculosis (TB) has started in South Africa, which has one of the highest burdens in the world.
Health

FDA approves expanded use of eculizumab for pediatric myasthenia gravis

HQ Team March 13, 2025: The U.S. Food and Drug Administration (FDA) has approved the expanded use of drug eculizumab (marketed as Soliris).

Read More